D. Boral Capital Reaffirms “Buy” Rating for Imunon (NASDAQ:IMNN)

Imunon (NASDAQ:IMNN)‘s stock had its “buy” rating restated by investment analysts at D. Boral Capital in a report released on Thursday,Benzinga reports. They presently have a $29.00 target price on the stock.

Other analysts have also issued research reports about the company. HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of Imunon in a research note on Wednesday, December 11th. EF Hutton Acquisition Co. I raised shares of Imunon to a “strong-buy” rating in a research note on Monday, September 23rd.

Imunon Price Performance

Shares of NASDAQ:IMNN opened at $0.83 on Thursday. The business has a 50 day simple moving average of $0.87 and a two-hundred day simple moving average of $1.07. Imunon has a 1 year low of $0.48 and a 1 year high of $3.65. The firm has a market capitalization of $12.04 million, a PE ratio of -0.44 and a beta of 2.12.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.